<unk>  is an investigational oncolytic virus that is in clinical trials for various cancers. It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1.<unk>  has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents. The T-SIGn vectors at clinical study stage are: * NG-350A: This vector contains two transgenes expressing the heavy and light chains for a secreted CD40 agonist monoclonal antibody. * NG-641: This vector contains four transgenes expressing secreted Interferon alpha, the chemokines CXCL9, CXCL10 and an anti-FAP/anti-CD3 bispecific T-cell activator In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated<unk>  as an orphan medicinal product for the treatment of ovarian cancer.
Enadenotucirev
Brexucabtagene autoleucel
Seviteronel
Voretigene neparvovec
Belantamab mafodotin
Crofelemer
Ciltacabtagene autoleucel
Idecabtagene vicleucel